Insider Transactions in Q2 2025 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
SELL
Open market or private sale
|
Direct |
41,314
-7.58%
|
$123,942
$3.67 P/Share
|
|
Jun 10
2025
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+18.08%
|
-
|
|
Jun 10
2025
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+18.16%
|
-
|
|
Jun 10
2025
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+21.11%
|
-
|
|
Jun 10
2025
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+15.11%
|
-
|
|
Jun 10
2025
|
Leanne M Zumwalt |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+24.6%
|
-
|
|
Jun 10
2025
|
Ron Frieson |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+21.61%
|
-
|
|
Jun 10
2025
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
35,700
+18.94%
|
-
|
|
Jun 09
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
15,000
-5.32%
|
$60,000
$4.01 P/Share
|
|
Jun 09
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.05%
|
$15,000
$1.68 P/Share
|
|
Jun 04
2025
|
Richard C Malabre SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
13,334
-4.76%
|
$40,002
$3.53 P/Share
|